What is Deciphex?
Deciphex is at the forefront of revolutionizing pathology with its digital pathology-based software and services tailored for both clinical and research applications. The company leverages artificial intelligence to augment the capabilities of pathologists, aiming to significantly improve their efficiency and accuracy. By addressing the growing disparity between the demand for pathology services and the available resources, Deciphex positions itself as a key innovator in a sector ripe for technological advancement. Their solutions are designed to tackle the most pressing issues in modern pathology, paving the way for a more connected and accelerated diagnostic future.
How much funding has Deciphex raised?
Deciphex has raised a total of $67.1M across 6 funding rounds:
Other Financing Round
$2.3M
Series A
$6.2M
Series B
$11.5M
Other Financing Round
$4.2M
Debt
$10.6M
Series C
$32.3M
Other Financing Round (2019): $2.3M, investors not publicly disclosed
Series A (2020): $6.2M led by Act Venture Capital Ltd, Enterprise Ireland, NextSteps Capital LLC, GI Partners of Illinois LLC, Halo Business Angel Network, and Irrus Investments
Series B (2022): $11.5M supported by Act Venture Capital and Charles River Laboratories India Private
Other Financing Round (2023): $4.2M featuring Seroba Life Sciences Management
Debt (2023): $10.6M backed by Claret Capital Partners
Series C (2025): $32.3M with participation from hban.cn, Seroba, Irrus Investments, Charles River, NextSteps Capital, ACT Venture Capital, and Molten Ventures
Key Investors in Deciphex
Claret Capital Partners
Claret Capital Partners is a prominent European growth lender that provides growth capital to innovative, growth-stage businesses. With extensive experience in technology financing, they offer debt solutions to help companies expand while minimizing dilution.
Act Venture Capital
Act Venture Capital is an Irish venture capital firm focused on investing in entrepreneurial and innovative companies, aiming to help them become leaders in international markets. They provide venture capital to support ambitious companies and build long-term value.
Seroba Life Sciences Management
Seroba Life Sciences Management is a European venture capital firm specializing in life sciences, focusing on biotech and medtech innovations. They partner with entrepreneurs to build businesses around scientific advancements and create value for investors.
What's next for Deciphex?
With the recent influx of major strategic investment and substantial overall capital, Deciphex is poised for significant expansion and innovation. The company's focus on integrating AI with digital pathology indicates a clear trajectory towards scaling its operations and enhancing its technological offerings. This substantial backing suggests a strong market validation and provides the necessary resources for Deciphex to further develop its platform, expand its reach into global markets, and solidify its position as a leader in the digital pathology revolution. Future developments are likely to center on deepening AI integration, broadening clinical adoption, and forging strategic partnerships to accelerate the transformation of pathology services.
See full Deciphex company page
